These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 27106406)

  • 1. Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma.
    McDonald CR; Delfanti RL; Krishnan AP; Leyden KM; Hattangadi-Gluth JA; Seibert TM; Karunamuni R; Elbe P; Kuperman JM; Bartsch H; Piccioni DE; White NS; Dale AM; Farid N
    Neuro Oncol; 2016 Nov; 18(11):1579-1590. PubMed ID: 27106406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal restriction spectrum imaging is resistant to pseudoresponse in patients with high-grade gliomas treated with bevacizumab.
    Kothari P; White NS; Farid N; Chung R; Kuperman JM; Girard HM; Shankaranarayanan A; Kesari S; McDonald CR; Dale AM
    AJNR Am J Neuroradiol; 2013 Sep; 34(9):1752-1757. PubMed ID: 23578667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas.
    Kong Z; Yan C; Zhu R; Wang J; Wang Y; Wang Y; Wang R; Feng F; Ma W
    Neuroimage Clin; 2018; 20():51-60. PubMed ID: 30069427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
    Buemi F; Guzzardi G; Del Sette B; Sponghini AP; Matheoud R; Soligo E; Trisoglio A; Carriero A; Stecco A
    Neuroradiol J; 2019 Aug; 32(4):241-249. PubMed ID: 31066622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining diffusion and perfusion differentiates tumor from bevacizumab-related imaging abnormality (bria).
    Farid N; Almeida-Freitas DB; White NS; McDonald CR; Kuperman JM; Almutairi AA; Muller KA; VandenBerg SR; Kesari S; Dale AM
    J Neurooncol; 2014 Dec; 120(3):539-46. PubMed ID: 25135423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased tumor apparent diffusion coefficient correlates with objective response of pediatric low-grade glioma to bevacizumab.
    Hsu CH; Lober RM; Li MD; Partap S; Murphy PA; Barnes PD; Fisher PG; Yeom KW
    J Neurooncol; 2015 May; 122(3):491-6. PubMed ID: 25758812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restriction Spectrum Imaging Improves Risk Stratification in Patients with Glioblastoma.
    Krishnan AP; Karunamuni R; Leyden KM; Seibert TM; Delfanti RL; Kuperman JM; Bartsch H; Elbe P; Srikant A; Dale AM; Kesari S; Piccioni DE; Hattangadi-Gluth JA; Farid N; McDonald CR; White NS
    AJNR Am J Neuroradiol; 2017 May; 38(5):882-889. PubMed ID: 28279985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab.
    Rahman R; Hamdan A; Zweifler R; Jiang H; Norden AD; Reardon DA; Mukundan S; Wen PY; Huang RY
    J Neurooncol; 2014 Aug; 119(1):149-58. PubMed ID: 24805151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normalization of ADC does not improve correlation with overall survival in patients with high-grade glioma (HGG).
    Qin L; Li A; Qu J; Reinshagen K; Li X; Cheng SC; Bryant A; Young GS
    J Neurooncol; 2018 Apr; 137(2):313-319. PubMed ID: 29383647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma.
    Nowosielski M; Recheis W; Goebel G; Güler O; Tinkhauser G; Kostron H; Schocke M; Gotwald T; Stockhammer G; Hutterer M
    Neuroradiology; 2011 Apr; 53(4):291-302. PubMed ID: 21125399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of intravoxel incoherent motion magnetic resonance imaging and arterial spin labeling for recurrent glioma after bevacizumab treatment.
    Miyoshi F; Shinohara Y; Kambe A; Kuya K; Murakami A; Kurosaki M; Ogawa T
    Acta Radiol; 2018 Nov; 59(11):1372-1379. PubMed ID: 29471670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gliomas: Histogram analysis of apparent diffusion coefficient maps with standard- or high-b-value diffusion-weighted MR imaging--correlation with tumor grade.
    Kang Y; Choi SH; Kim YJ; Kim KG; Sohn CH; Kim JH; Yun TJ; Chang KH
    Radiology; 2011 Dec; 261(3):882-90. PubMed ID: 21969667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients.
    Zhang M; Gulotta B; Thomas A; Kaley T; Karimi S; Gavrilovic I; Woo KM; Zhang Z; Arevalo-Perez J; Holodny AI; Rosenblum M; Young RJ
    Neuro Oncol; 2016 May; 18(5):735-43. PubMed ID: 26538618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival.
    Chen C; Huang R; MacLean A; Muzikansky A; Mukundan S; Wen PY; Norden AD
    J Neurooncol; 2013 Nov; 115(2):267-76. PubMed ID: 23974656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurements of diagnostic examination performance using quantitative apparent diffusion coefficient and proton MR spectroscopic imaging in the preoperative evaluation of tumor grade in cerebral gliomas.
    Server A; Kulle B; Gadmar ØB; Josefsen R; Kumar T; Nakstad PH
    Eur J Radiol; 2011 Nov; 80(2):462-70. PubMed ID: 20708868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of two region-of-interest placement methods for histogram analysis of apparent diffusion coefficient maps for glioma grading.
    Hieu ND; Hung ND; Hung ND; Hien MM; Anh DV; Dung LT
    Clin Ter; 2024; 175(3):128-136. PubMed ID: 38767069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ADC texture--an imaging biomarker for high-grade glioma?
    Brynolfsson P; Nilsson D; Henriksson R; Hauksson J; Karlsson M; Garpebring A; Birgander R; Trygg J; Nyholm T; Asklund T
    Med Phys; 2014 Oct; 41(10):101903. PubMed ID: 25281955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advantages of high b-value diffusion-weighted imaging to diagnose pseudo-responses in patients with recurrent glioma after bevacizumab treatment.
    Yamasaki F; Kurisu K; Aoki T; Yamanaka M; Kajiwara Y; Watanabe Y; Takayasu T; Akiyama Y; Sugiyama K
    Eur J Radiol; 2012 Oct; 81(10):2805-10. PubMed ID: 22100373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Invasion is not an independent prognostic factor in high-grade glioma.
    Narayana A; Perretta D; Kunnakkat S; Gruber D; Golfinos J; Parker E; Medabalmi P; Zagzag D; Pat Eagan RN; Gruber M
    J Cancer Res Ther; 2011; 7(3):331-5. PubMed ID: 22044816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Early Response to Anti-Angiogenic Therapy in Recurrent Glioblastoma: Amide Proton Transfer-weighted and Perfusion-weighted MRI compared with Diffusion-weighted MRI.
    Park JE; Kim HS; Park SY; Jung SC; Kim JH; Heo HY
    Radiology; 2020 May; 295(2):397-406. PubMed ID: 32154775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.